THREEWIRE, LLC – Trademark Portfolio
Entity Type: 16
THREEWIRE, LLC holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 7 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include FASTER, THREEWIRE, MY PATIENT, MY-PATIENT.COM, and COMMUNITY HEALTH TALKS. The owner is based in PRINCETON, NJ.
212 CARNEGIE CENTER, SUITE 301
PRINCETON, NJ 08540
Showing of trademarks Trademarks
Trademark Classifications
THREEWIRE, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does THREEWIRE, LLC have?
THREEWIRE, LLC has 8 U.S. trademarks filed with the USPTO. Of these, 6 registered, 2 cancelled.
What trademark classes does THREEWIRE, LLC file in?
THREEWIRE, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 41 (Education & Entertainment). Class 35 covers advertising; business management; business administration; office functions.
What are THREEWIRE, LLC's most well-known trademarks?
THREEWIRE, LLC's registered trademark portfolio includes well-known marks such as FASTER, THREEWIRE, MY PATIENT, MY-PATIENT.COM, and COMMUNITY HEALTH TALKS. These are among 6 currently registered trademarks in the portfolio.
What is THREEWIRE, LLC's trademark registration success rate?
THREEWIRE, LLC has a 75% trademark registration rate, with 6 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.